CJC-1295 no DAC + Ipamorelin

Client Peptide Bros · Blend 5 mg / 5 mg · Acetate salt

VERIFIED ID **NP-B7RCI5-CIPA**

Sample as received

CLIENT
Peptide Bros

SAMPLE REFERENCE
NPA-26-09057

CLIENT LOT
PB-CJCIPA-5-5-2609

DATE RECEIVED
05 Sep 2026

DATE ANALYSED
10 Sep 2026

DATE ISSUED
11 Sep 2026

Scan QR to verify

HPLC PURITY (AREA %)

99.59 / 99.33%

Two resolved main peaks · 214 nm

IDENTITY (ESI-MS)

Confirmed

Ipamorelin 711.89 / 711.86 Da

CJC no DAC 3368.02 / 3367.90 Da

NET CONTENT

5.23 / 5.31 mg

Appearance: white lyophilized cake

Endotoxin: not requested

COLUMN / METHOD
C18 4.6 × 250 mm, 5 µm · H2O/MeCN + 0.1% TFA

MAIN PEAK RT
5.21 / 8.94 min

ANALYST
A. Chen, M.Sc.

REVIEWER
R. Singh, Ph.D.

LABORATORY
Vancouver, BC

Statement

The results above describe the sample as received under the sample reference on this certificate. They do not certify any other vial, lot, or subsequent handling. HPLC purity is chromatographic area percent and is not net peptide content. Identity is intact-mass agreement with the theoretical mass of the named sequence.

Electronically issued. Verify at the URL encoded in the QR code. Printed copies are uncontrolled.
NorthPeak Analytical Ltd. does not manufacture or sell peptides.

Chromatogram and peak table

RP-HPLC-UV 214 nm · Sample NPA-26-09057 · NP-B7RCI5-CIPA



Integrated peaks

#	RT (min)	Area %	Assignment
1	**5.21**	**49.73**	**Ipamorelin (main peak)**
2	5.74	0.31	Related impurity
3	**8.94**	**49.67**	**CJC-1295 no DAC (main peak)**
4	9.61	0.51	Related impurity

Method notes

Mobile phase A: water + 0.1% TFA. Mobile phase B: acetonitrile + 0.1% TFA.
Gradient: 5–65% B over 12 min, 1.0 mL/min, column 30 °C, injection 10 µL.
Component purity is reported per peptide against the integrated peak set at 214 nm.
Salts, counter-ions and residual water are not quantified by UV and are not reported as HPLC impurities.
Mass confirmation by positive-mode ESI. Acceptance: observed mass within ±0.5 Da of theory for this peptide class.